LRRC44 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-83159
Key Product Details
Species Reactivity
Validated:
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Summary for LRRC44 Antibody
Immunogen
The immunogen is a synthetic peptide directed towards the C-terminal region of Human LRRC44. Peptide sequence: LRTFSDIDKYYTEQKKQEYHKEKVRVVAMAQVARERVRVAVNEHLNQKKY The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Scientific Data Images for LRRC44 Antibody
![Western Blot: LRRC44 Antibody [NBP2-83159]](https://resources.bio-techne.com/images/products/LRRC44-Antibody-Western-Blot-NBP2-83159-img0001.jpg "Western Blot: LRRC44 Antibody [NBP2-83159]")
Western Blot: LRRC44 Antibody [NBP2-83159]
Western Blot: LRRC44 Antibody [NBP2-83159] - Host: Rabbit. Target Name: LRRIQ3. Sample Type: Hela Whole Cell lysates. Antibody Dilution: 1.0ug/mlApplications for LRRC44 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: LRRC44
Alternate Names
leucine rich repeat containing 44, leucine-rich repeat and IQ domain-containing protein 3, Leucine-rich repeat-containing protein 44, leucine-rich repeats and IQ motif containing 3, LRRC44, MGC22773
Gene Symbol
LRRIQ3
Additional LRRC44 Products
Product Specific Notices for LRRC44 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...